MabVax Therapeutics and Telik join forces

Cancer immunotherapy company MabVax Therapeutics and Telik, a clinical stage oncology drug development company have entered into a definitive merger agreement. MabVax is backed by Numoda Capital Innovations, Burrill Capital and RTP Venture Fund.

MabVax Therapeutics Secures First Series B Tranche

MabVax Therapeutics, a privately held clinical stage biotechnology company has closed the first tranche in a Series B financing. Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget